Obstructive sleep apnoea and 12-month weight loss in adults with class 3 obesity attending a multidisciplinary weight management program

Sophie Kobuch 1, Fiona Tsang 2, Ritesh Chimoriya 1, Daniel Gossayn 1, Sarah O’Brien 1, Javeria Jamal 1, Leon Laks 3, Abd Tahran 4,5,6, Nic Kormas 2 and Milan K Piya 1,2,7*

Abstract

Background: Although there is a strong association between obesity and obstructive sleep apnoea (OSA), the effects of OSA and CPAP therapy on weight loss are less well known. The aim of this study in adults with class 3 obesity attending a multidisciplinary weight management program was to assess the relationship between OSA and CPAP usage, and 12-month weight change.

Methods: A retrospective cohort study of all patients commencing an intensive multidisciplinary publicly funded weight management program in Sydney, Australia, between March 2018 and March 2019. OSA was diagnosed using laboratory overnight sleep studies. Demographic and clinical data, and use of CPAP therapy was collected at baseline and 12 months. CPAP use was confirmed if used ≥4 h on average per night on download.

Results: Of the 178 patients who joined the program, 111 (62.4 %) completed 12 months in the program. At baseline, 63.1 % (n=70) of patients had OSA, of whom 54.3 % (n=38) were using CPAP. The non-OSA group had more females compared to the OSA with CPAP group and OSA without CPAP group (90.2 % vs. 57.9 % and 62.5 %, respectively; p=0.003), but there were no significant baseline differences in BMI (50.4±9.3 vs. 52.1±8.7 and 50.3±9.5 kg/m 2, respectively; p=0.636). There was significant weight loss across all three groups at 12 months. However, there were no statistically significant differences across groups in the percentage of body weight loss (OSA with CPAP: 6.3±5.6 %, OSA without CPAP: 6.8±6.9 %, non-OSA: 7.2±6.5 %; p=0.844), or the proportion of patients who achieved ≥5 % body weight loss (OSA with CPAP: 57.9 %, OSA without CPAP: 59.4 %, non-OSA: 65.9 %; p=0.743). In patients with T2DM, there was a significant reduction in HbA1c from baseline to 12 months (7.8±1.7 % to 7.3±1.4 %, p=0.03), with no difference between groups (p=0.997).

* Correspondence: m.piya@westernsydney.edu.au

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusions: This multidisciplinary weight management program resulted in significant weight loss at 12 months, regardless of OSA diagnosis or CPAP use in adults with class 3 obesity. Larger studies are needed to further investigate the effects of severity of OSA status and CPAP use in weight management programs. Until completed, this study suggests that the focus should remain on implementing lifestyle changes and weight management regardless of OSA status.

Keywords: Obstructive sleep apnoea, Continuous positive airway pressure (CPAP), Weight management, Class 3 obesity

Background
Obesity is a complex medical condition which is impacted by a variety of factors such as genetics, environment, culture and individual lifestyle [1]. Class 3 obesity refers to individuals with a body mass index (BMI) greater than 40 kg/m² and is linked to increased mortality as well as risk of a range of health concerns including hypertension, type 2 diabetes (T2DM), coronary artery disease, and obstructive sleep apnoea (OSA) [1, 2]. The relationship between class 3 obesity and these conditions is often reciprocal with evidence suggesting an interplay between obesity, T2DM and OSA, which results in an increase in incidence and severity of all three [3–5].

OSA is a condition characterized by recurrent loss of tone of the upper airway resulting in hypopnoea (partial obstruction) and apnoea (complete obstruction) causing hypoxia and subsequent waking from sleep [6]. It is a significant contributor to motor vehicle accidents when not treated [7], and has been shown to exacerbate long-term diabetes complications such as cardiovascular disease (CVD), neuropathy, retinopathy and nephropathy [8–11]. While polysomnography is the “gold standard” for OSA diagnosis, it is often not widely used due to its costs and reduced availability. In virtue of this, questionnaires are valuable for the screening of the disease. These include the Epworth Sleepiness Scale (ESS), the Berlin Questionnaire (BQ) as well as the STOP-Bang Questionnaire [12, 13].

First line treatment for moderate to severe OSA is continuous positive airway pressure (CPAP) [14]. Unfortunately, compliance with CPAP at one year is estimated to be as low as 50 % due to discomfort experienced by patients, challenging treatment titration processes, cost of CPAP and other psychological factors [4, 15–17].

Obesity can affect the pathogenesis of OSA in multiple ways, including upper airway fat deposition and muscle impairment, pressure from abdominal fat, leptin resistance and increased inflammatory state [18]. Significant weight loss can also reduce symptoms of OSA [14, 19, 20], but long term weight loss which is sufficient enough to reduce the severity of OSA in individuals with class 3 obesity is difficult to achieve and maintain, particularly without bariatric surgery [21–23]. On the other hand, the role of OSA on weight gain and the development of obesity is more controversial. Several factors could affect the pathogenesis of obesity in people with OSA, including daytime sleepiness and associated reduced physical activity as well as sleep deprivation affecting hunger and satiety hormones, and altering brain activity in the reward centre [18, 24, 25]. This controversy is not helped by the fact that a meta-analysis of 25 randomised trials suggested an increase in weight over time for people with OSA using CPAP therapy [26]. One explanation for this is the reduction in sympathetic activation and leptin levels following CPAP treatment which could lead to weight gain [27, 28]. However, the trials included in the meta-analysis were not from weight management programs, nor in people with class 3 obesity. It is important to understand the impact of OSA and CPAP on weight outcomes within the context of a weight management program. Therefore, the aims of this study in people with class 3 obesity were:

1. To compare weight loss over 12 months between patients with and without OSA.
2. Among patients with OSA, to compare weight loss over 12 months between those who used CPAP for ≥4 h/night and those who did not.
3. To determine whether the baseline Epworth Sleepiness Scale score is associated with weight loss at 12 months.

Methods
This was a retrospective cohort study conducted in a publicly funded, hospital based, intensive, multidisciplinary weight management program in greater Sydney, which has been previously described [29, 30]. Patients included in the study had been enrolled in the program between March 2018 and March 2019, were over 18 years of age, had a BMI ≥40 kg/m², and had at least 12 months follow up in the program. Patients attended two education sessions prior to their first medical appointment with a physician. The multidisciplinary team is comprised of endocrinologists, gastroenterologist, diabetes specialist nurse (educator), dietitians, clinical psychologists, physiotherapists, and a psychiatrist, with patients being reviewed by a local sleep physician for OSA screening and CPAP therapy use/compliance.
Patients are provided individualised care every 4-12 weeks depending on clinical need and availability. The study was approved by the South West Sydney Local Health District (SWSLHD) Human Research Ethics Committee as a Quality Assurance Project (Reference: CT22_2018).

**Measurements**

Electronic and paper records were reviewed to obtain demography, anthropometry and medical details including medications, blood results and sleep data. At each visit, weight was recorded on the same scale. Weight loss at 12 months was measured as both kilograms lost and as the percentage change from baseline weight. Every patient completed the Epworth Sleepiness Scale (ESS) [13] and Berlin Questionnaire at baseline, and the ESS at the 12 month visit, regardless of previous diagnosis of OSA or use of CPAP. The ESS is a self-administered questionnaire which measures a person’s general level of daytime sleepiness during commonly encountered situations. OSA was confirmed with diagnostic laboratory sleep studies before or soon after program commencement. CPAP compliance was considered if treated with an average of ≥4 h/night on download. Any data collected between 11 and 13 months was considered for the 12-month time frame due to variations in follow up appointments. Data was de-identified before analysis.

**Data analysis**

Differences in baseline between three groups on the basis of OSA diagnosis and CPAP use: OSA with CPAP, OSA without CPAP, and non-OSA groups, were evaluated for patients completing 12-month follow up. Kolmogorov–Smirnov test and Shapiro–Wilk test were performed to test normality of the data. Analysis of variance (ANOVA) was conducted for continuous variables with normal distribution, Kruskal–Wallis test for continuous data without normal distribution, and Pearson’s chi-square test for categorical variables. Analysis of covariance (ANCOVA) was conducted to evaluate the changes across the three groups and adjust for the covariates. Paired sample t-tests and Wilcoxon signed rank test were used to test for differences between baseline and 12 months within each group. Weight loss at 12 months was reported as percentage body weight loss. Relationships between continuous variables were determined through the Pearson’s correlation coefficient. P<0.05 was considered statistically significant. All statistical analyses were performed with the Statistical Package for Social Sciences (SPSS) Version 25.

**Results**

A total of 178 patients joined the South Western Sydney Metabolic Rehabilitation and Bariatric Program between March 2018 and March 2019. Of those, 111 (62.4%) attended follow-up at 12 months and had data available as shown in Fig. 1.

**Baseline characteristics**

The baseline data of patients were categorised into three groups on the basis of OSA diagnosis and CPAP use: OSA with CPAP, OSA without CPAP, and non-OSA groups (Table 1). OSA had been diagnosed at baseline in 63.1% (n=70) of patients, of whom 54.3% (n=38) were using CPAP. The non-OSA group had more females compared to OSA with CPAP and OSA without CPAP groups (90.2 % vs. 57.9 % and 62.5 %, respectively; p=0.003). There were no significant baseline differences in age (50.6 ± 14.7 vs. 57.0 ± 12.4 and 53.5 ± 10.9 years, respectively; p=0.100), weight (134.9 ± 29.2 vs. 148.1 ± 31.3 and 140.4 ± 26.6 kg, respectively; p=0.137), or BMI (50.4 ± 9.3 vs. 52.1 ± 8.7 and 50.3 ± 9.5 kg/m², respectively; p=0.636) across all groups. The OSA without CPAP group had a higher proportion of participants with gastroesophageal reflux disease (GORD) compared to OSA with CPAP and non-OSA groups (62.5 % vs. 34.2 % and 43.9 %, p=0.039). However, there were no significant differences between the three groups in the proportion of patients who had hypertension, type 2 diabetes, dyslipidaemia, cardiovascular disease, or non-alcoholic fatty liver disease, with no differences in the baseline lipid profile and baseline ALT as depicted in Table 1.

At baseline, 34 patients (89.5 %) in the OSA with CPAP group, 28 patients (87.5 %) in the OSA without CPAP group, and 32 patients (78.0 %) in the non-OSA group completed the Berlin questionnaire. The majority of patients had a high-risk Berlin score in all three groups, with no significant differences between the three groups (p=0.532). All participants completed the ESS questionnaire at baseline, with no statistically significant differences in the baseline ESS score when compared across all three groups.

**Baseline vs. 12 months**

**Changes in Weight and ESS score**

Significant weight loss was observed across all three groups at 12 months (Fig. 2). However, there were no statistically significant differences in weight change at 12 months between the three groups (Table 2). Having a diagnosis of OSA did not affect percentage body weight loss at 12 months (p=0.610), nor the proportion of patients who achieved 5 % weight loss (p=0.449), nor who achieved 10 % weight loss (p=0.897). There was also no statistically significant association of CPAP use with weight loss at 12 months (p=0.774).

There was a significant reduction in the ESS score from baseline to 12 months in all three groups—OSA with CPAP: 7.7 ± 5.3 vs. 4.2 ± 5.6, p<0.001; OSA without CPAP: 8.5 ± 4.8 vs. 6.0 ± 6.2, p<0.034; non-OSA: 5.8 ±
5.1 vs. 2.7 ± 3.1, \( p < 0.001 \). However, there were no significant differences in change in ESS score at 12 months across the three groups—OSA with CPAP: 3.5 ± 5.9, OSA without CPAP: 2.5 ± 6.3, non-OSA: 3.1 ± 5.1; \( p = 0.753 \) (Table 2). There was also no significant correlation between percentage weight loss and change in ESS score at 12 months \( (r=0.08, p=0.398) \).

**Changes in lipid profile**

There was a significant difference in the decrease in cholesterol at 12 months across the three groups \( (p=0.010) \), which remained significant when adjusted for age and baseline weight (Table 2). Furthermore, it was revealed that the reduction in cholesterol at 12 months was statistically significant in the OSA with CPAP group (baseline: 4.6 ± 1.1 mmol/L vs. 12 months: 3.8 ± 0.8 mmol/L, \( p < 0.001 \)), but not in the OSA without CPAP group (baseline: 4.4 ± 0.9 mmol/L vs. 12 months: 4.3 ± 0.9 mmol/L, \( p = 0.342 \)), nor in the non-OSA group (baseline: 4.2 ± 1.0 mmol/L vs. 12 months: 4.5 ± 1.4 mmol/L, \( p = 0.368 \)) as presented in Fig. 3. There were no significant changes in HDL and triglyceride in all three groups between baseline and 12 months. There was no significant difference across the three groups in the change in triglyceride, HDL and LDL at 12 months as demonstrated in Table 2. However, there was a significant decrease in LDL at 12 months in the OSA with CPAP group (2.4 ± 1.1 mmol/L vs. 1.5 ± 0.9 mmol/L, \( p = 0.018 \)), but not in the OSA without CPAP group (2.6 ± 0.8 mmol/L vs. 2.3 ± 1.0 mmol/L, \( p = 0.733 \)), nor in the non-OSA group (2.2 ± 1.0 mmol/L vs. 2.2 ± 0.5 mmol/L, \( p = 0.924 \)) as presented in Fig. 3. There were no significant changes in HDL and triglyceride in all three groups between baseline and 12 months. There was no significant difference in the overall number of patients on cholesterol medication at baseline compared to 12-months (58.5 % vs. 64.0 %, \( p = 0.408 \)), and no significant difference within each group: OSA with CPAP group (65.8 % vs. 71.1 %, \( p = 0.621 \)), the OSA without CPAP group (59.4 % vs. 65.6 %, \( p = 0.605 \)), or in the non-OSA group (51.2 % vs. 56.1 %, \( p = 0.658 \)).

**Patients with diabetes**

There was no significant difference in the percentage of patients in each group who had a diagnosis of T2DM at
| Variable                               | Mean±SD or n(%) | OSA (n=70) | OSA with CPAP (n=38) | OSA without CPAP (n=32) | Non-OSA (n=41) | p value* |
|----------------------------------------|-----------------|------------|----------------------|-------------------------|----------------|----------|
| Age (years)                            | 57.0 ± 12.4     | 53.5 ± 10.9| 50.6 ± 14.7          | 0.100                   |                |          |
| Female                                 | 22 (57.9 %)     | 20 (62.5 %)| 23 (71.9 %)          | 0.636                   |                |          |
| Caucasian                              | 24 (63.2 %)     | 23 (71.9 %)| 17 (53.1 %)          | 0.230                   |                |          |
| Not in paid employment                 | 27 (71.1 %)     | 20 (68.8 %)| 20 (68.8 %)          | 0.112                   |                |          |
| Weight (kg)                            | 148.1 ± 31.3    | 140.4 ± 26.6| 134.9 ± 29.2         | 0.137                   |                |          |
| BMI (kg/m²)                            | 52.1 ± 8.7      | 50.3 ± 9.5 | 50.4 ± 9.3           | 0.294                   |                |          |
| Hypertension                           | 28 (73.7 %)     | 23 (71.9 %)| 24 (58.5 %)          | 0.528                   |                |          |
| T2DM                                   | 26 (68.4 %)     | 20 (62.5 %)| 23 (56.1 %)          | 0.528                   |                |          |
| Dyslipidaemia                          | 28 (73.7 %)     | 25 (78.1 %)| 25 (78.1 %)          | 0.240                   |                |          |
| Cardiovascular disease                 | 9 (23.7 %)      | 6 (18.8 %)| 5 (12.2 %)           | 0.441                   |                |          |
| Non-Alcoholic Fatty liver disease (NAFLD) | 5 (13.2 %)  | 7 (21.9 %)| 6 (14.6 %)           | 0.579                   |                |          |
| Gastro-oesophageal Reflux Disease (GORD) | 13 (34.2 %)  | 20 (62.5 %)| 18 (43.9 %)          | 0.039                   |                |          |
| Total Cholesterol (mmol/L)             | 4.5 ± 1.1       | 4.4 ± 0.9 | 4.4 ± 1.2            | 0.880                   |                |          |
| Triglycerides (mmol/L)                 | 1.9 ± 1.5       | 1.8 ± 0.8 | 1.8 ± 0.8            | 0.845                   |                |          |
| LDL Cholesterol (mmol/L)               | 2.5 ± 1.0       | 2.5 ± 0.7 | 2.4 ± 1.2            | 0.925                   |                |          |
| HDL Cholesterol (mmol/L)               | 1.1 ± 0.3       | 1.1 ± 0.3 | 1.2 ± 0.3            | 0.642                   |                |          |
| ALT (IU/L)                             | 33.4 ± 23.5     | 27.8 ± 13.4| 30.2 ± 14.5          | 0.447                   |                |          |
| Epworth Sleepiness Scale score         | 7.7 ± 5.3       | 8.5 ± 4.8 | 5.8 ± 5.1            | 0.078                   |                |          |
| Berlin Score                           | 2.5 ± 0.7       | 2.4 ± 0.7 | 2.3 ± 0.7            | 0.532                   |                |          |

*p-values reflects the difference across three groups.

**Fig. 2** Weight change from baseline to 12 months across the three groups. (Data expressed as mean ± SD in the graphs)
baseline (OSA with CPAP: 68.4 %, OSA without CPAP: 62.5 %, non-OSA: 56.1 %; p=0.528). Of the patients with T2DM, 38.4 % in the OSA with CPAP group, 30 % in the OSA without CPAP group and 30.4 % in the non-OSA group were on insulin at baseline. There was no significant difference in the proportion across the three groups (p=0.778), with an average daily insulin dose of 173.9 ± 106.9 units for OSA with CPAP, 109.7 ± 56.7 units for OSA without CPAP, and 102.1 ± 54.0 units for the non-OSA group (p=0.366).

At 12 months, among patients with T2DM, 42.3 % in the OSA with CPAP group, 30 % in the OSA without CPAP group and 26.1 % in the non-OSA group were on insulin (p=0.0448). The average daily insulin dose was 106.9 ± 65.6 U for OSA with CPAP, 56.7 ± 56.3 U for OSA without CPAP, and 54.0 ± 25.9 U for non-OSA group (p=0.370). From baseline to 12 months, there was no significant difference in the proportion of patients on insulin across all three groups. There were statistically significant reductions in insulin dose across two groups (OSA with CPAP: p=0.014; non-OSA: p=0.002), and non-significant reduction in insulin dose in the OSA without CPAP group (p=0.194). In the overall study population, there was a significant reduction in HbA1c from baseline to 12 months (7.8±1.7 % to 7.3±1.4 %, p=0.03), with no difference in the reduction in HbA1c across three groups (OSA with CPAP: 0.5 ± 1.5 %, OSA without CPAP: 0.5 ± 1.1 %, non-OSA: 0.6 ± 1.6 %, p=0.997).

**Discussion**

In this single centre cohort study, individuals with class 3 obesity attending a publicly funded weight management program had significant weight loss in both those with and without OSA. There was no significant difference in weight loss between the groups, and the use of CPAP in the OSA group did not affect the 12-month weight outcomes.

Although significant, the percentage weight loss over the 12-month period in this high-risk population was modest (6-7 %), which is akin to previous studies [29–31]. The impact of OSA on obesity is not completely understood. While multiple mechanisms would logically link the sleep deprivation experienced by patients with OSA to weight gain such as reduction in physical activity and eating behaviours favouring high calorie containing foods [32, 33], as well as an activation of the hypothalamic-pituitary-adrenal axis and increased cortisol, the long term evidence of the impact of OSA on weight is sparse [34]. While the increased tiredness and sleepiness often associated with OSA would not favour successful weight loss interventions, patients who use CPAP generally report dramatic improvements in alertness, mood and quality of life, each of which may be essential in attempting to lose weight [35]. However, a systematic review of over 3000 patients from 25 randomised controlled trials suggested an increase in weight over time for people with OSA using CPAP therapy [26], that was greater with increasing baseline weight. Thus, it is perhaps not surprising that in this study, those with OSA treated with CPAP did not appear to have improved weight loss compared to those with untreated OSA. Therefore, weight loss in OSA patients seems to be multifactorial, and cannot at this stage be solely achieved with CPAP therapy. Indeed, multiple factors have been hypothesised for this finding, including the

**Table 2** Changes in weight, lipid profile and Epworth Sleepiness Scale score between baseline and 12 months across the three groups of participants: OSA with CPAP, OSA without CPAP, and non-OSA

| Variable                                      | OSA (n=71)   | Non-OSA (n=41) | Unadjusted p value | P-value adjusted for age and baseline weight |
|-----------------------------------------------|--------------|----------------|-------------------|--------------------------------------------|
| Weight Change at 12 months                   |              |                |                   |                                            |
| Weight loss (in kg)                          | 9.1 ± 7.9    | 9.2 ± 9.9      | 9.9 ± 9.6         | 0.903                                       |
| Percentage of body weight loss               | 6.3 ± 5.6    | 6.8 ± 6.9      | 7.2 ± 6.5         | 0.844                                       |
| More than 5 % body weight loss               | 22 (57.9 %)  | 19 (59.4 %)    | 27 (65.9 %)       | 0.743                                       |
| Change in Lipid profile                      |              |                |                   |                                            |
| Cholesterol (mmol/L)                         | 0.8 ± 1.1    | 0.1 ± 1.3      | -0.3 ± 1.6        | 0.010                                       |
| Triglyceride (mmol/L)                        | 0.3 ± 1.8    | -0.2 ± 1.4     | -0.5 ± 2.6        | 0.318                                       |
| HDL (mmol/L)                                 | 0.1 ± 0.4    | 0.1 ± 0.5      | 0.0 ± 0.4         | 0.912                                       |
| LDL (mmol/L)                                 | 0.8 ± 1.1    | 0.4 ± 1.4      | 0.0 ± 1.0         | 0.140                                       |
| Change in Epworth Sleepiness Scale (ESS) score at 12 months |              |                |                   |                                            |
| ESS Score                                    | 3.5 ± 5.9    | 2.5 ± 6.3      | 3.1 ± 5.1         | 0.753                                       | 0.399
reduction in sympathetic activity leading to reduced lipolysis and energy expenditure, leading to weight gain [26]. Of note, the systematic review did not evaluate the effect of CPAP on weight loss among patients following a weight management program. Furthermore, these studies did not evaluate the weight loss in people with class 3 obesity.

While there may be the preconceived notion that being diagnosed with OSA impacts on the ability for patients to lose weight, our study suggests that weight loss outcomes are similar, regardless of the presence of OSA diagnosis at baseline or the use of CPAP. This has implications for both patients and clinicians alike, in alleviating the concerns of how OSA diagnosis or use of CPAP may impact weight loss. Instead, emphasis can be placed on implementing lifestyle changes that may induce a modest amount of weight loss that can be beneficial to the metabolic risk profile of individuals with class 3 obesity [3, 36].

There are, however, undeniable benefits of CPAP therapy in improving OSA severity and thereby sleep quality on overall health. Several studies have shown a high prevalence of T2DM in patients with OSA and vice versa [37, 38], OSA being an independent risk factor for the development of T2DM [39]. We have recently demonstrated that patients with class 3 obesity had a reduction in their HbA1c by 0.47% over 6 months in this weight management program [30]. In this study, we report no difference at baseline in the proportion of patients who have T2DM, nor in the daily dose of insulin in all three groups. However, the reduction in HbA1c was consistent with our previous study and was similar regardless of CPAP use. This supports the notion that OSA diagnosis or CPAP use may not affect glycaemic control, in the parameters of a medical weight management program in people with class 3 obesity. There are inconsistent findings in the effects of CPAP use for 1-6

---

**Note:** p-values are only reported for statistically significant changes.

**Fig. 3** Changes in lipid profiles from baseline to 12 months across three groups
months on improvement of glycaemic control [40–43]. Well-controlled experiments with compliant CPAP use for 8 h a night have shown to improve glucose metabolism in one to two weeks [44, 45]. However, the largest study to date which included close to 900 participants followed over 4.3 years showed no significant difference between the CPAP and usual care groups in their serum glucose or HbA1c [46]. Larger studies of longer duration are needed to assess the impact of CPAP on the prevention of T2DM.

People with OSA on CPAP had a significant drop in the total and LDL cholesterol levels at 12 months compared to baseline, whereas there was no significant change in those with OSA not on CPAP, nor in those without OSA. This is interesting, given that there were no differences in use of cholesterol lowering medications overall or in any of the groups from baseline to 12 months. While clear evidence of the benefits of CPAP use on reducing cholesterol levels is lacking, it has been postulated that CPAP may improve patients’ lipid profile by reducing the intermittent hypoxia, as well as through increased physical activity [47]. These findings should be confirmed in larger trials, and possible mechanisms warrant further investigation.

Hypertension is another well-known risk factor for cardiovascular disease and overall mortality. Blood pressure decreases during sleep, which is likely related to decreases in sympathetic output. A lack of this “nocturnal dipping”, which is inevitably the case in patients with OSA, has been associated with a greater risk of cardiovascular mortality [48]. Even a 10mm Hg increase in mean night-time systolic blood pressure has been shown to be associated with a 21 % increase in cardiovascular mortality [49]. Multiple large studies have shown that people who sleep less than five hours per night have a greater risk of hypertension than those sleeping more than 7 h per night [50, 51]. Therefore, it seems logical that improving sleep would reduce the incidence of hypertension in patients with OSA. A retrospective study in patients with T2DM and newly diagnosed OSA, showed that the use of CPAP for 9-12 months lead to a significant reduction in blood pressure [52]. Thus, improving OSA severity and thereby increasing sleep quality has the potential to substantially improve cardiovascular morbidity and mortality. Hence, it is encouraging to see a significant reduction in the Epworth Sleepiness Scale score over a 12-month period in all three groups in our study. In addition to the benefits of reduced sleepiness on driving and day to day functioning, it may be that the benefits of the reduction in sleepiness on weight outcomes are seen later than at the 12-month period.

As many patients in this study, and people with class 3 obesity in general, would often meet the criteria for bariatric surgery, it is of utmost importance to optimise pre-operative health, including OSA severity, to minimise peri-operative complications. Indeed, there is a positive association between OSA severity and post-operative risk, including increased risk of shock and cardiac arrest [53]. Therefore, improving OSA status prior to bariatric surgery may prevent peri-operative complications. In virtue of this, clinicians and allied health professionals should focus on emphasising improvements in OSA status, and herewith CPAP compliance, in addition to weight loss per se, in patients with class 3 obesity.

The main strength of this study is that it is based in a real-world weight management program, that included all patients from a publicly funded metabolic program within a hospital service. These findings can therefore inform other multidisciplinary medical weight management programs. Limitations are that this is a single centre with a relatively small cohort of patients, and only 12 months follow up. Multicentre studies which include large sample sizes and longer follow up would help corroborate the findings from this study. Furthermore, a larger sample size would have allowed us to assess the severity of OSA, and its impact on weight loss. Finally, reasons for why patients did or did not commence CPAP were not explored in this study. Such analysis may help identify barriers not only to CPAP use, but also to weight loss.

Conclusions
This single centre retrospective cohort study demonstrated that the presence of OSA at baseline or the use of CPAP does not affect weight or glycaemic outcomes at 12 months in people with class 3 obesity in the context of a medical weight management program. Findings from this study suggest that the focus should remain on implementing lifestyle changes and medical weight management in people with class 3 obesity, regardless of OSA status.

Abbreviations
ALT: alanine aminotransferase; ANOVA: analysis of variance; ANCOVA: analysis of covariance; BMI: Body Mass Index; BQ: Berlin Questionnaire; CPAP: continuous positive air pressure; CVD: cardiovascular disease; ESS: Epworth Sleepiness Scale; HbA1c: glycosylated hemoglobin; HDL: high density lipoprotein; IU/L: international units per litre; kg: kilogram; kg/m²: kilogram per meter squared; LDL: low density lipoprotein; mmol/L: millimoles per litre; OSA: obstructive sleep apnoea; SD: standard deviation; SES: socioeconomic status; SPSS: Statistical package for social sciences; SWSL HD: South West Sydney Local Health District; SWS MRBP: South Western Sydney Metabolic Rehabilitation and Bariatric Program; T2DM: type 2 diabetes mellitus; U: units

Acknowledgements
The authors would like to thank all the patients and staff in the South Western Sydney Metabolic Rehabilitation and Bariatric Program (SWS MRBP) at Camden Hospital. The help from Kyaw Phone Myint, Kathryn Skelsey, Kathy Grudzinskas and Hayley O’Donnell is particularly appreciated.
Authors’ contributions
SK made a substantial contribution to the concept and design, data collection and analysis and interpretation of data, and drafting of the article. FT and DG made a substantial contribution to data collection, analysis and interpretation of data and drafting of the article. RC made a substantial contribution to data analysis and drafting of the article. SO and JJ made a substantial contribution to the concept and design, data analysis and interpretation of data, and revised the article critically for important intellectual content. MKP made a substantial contribution to the concept and design, data analysis and drafting of the article. AT revised the article critically for important intellectual content. All authors read and approved the final manuscript.

Funding
The study was funded from internal departmental funds from Western Sydney University.

Availability of data and materials
The datasets used and analysed during the current study are available from Sydney University.

Declarations

Ethics approval and consent to participate
All methods were performed in accordance with the Declaration of Helsinki, and this study was approved by the South Western Sydney Local Health District (SWLHD) Research Ethics Committee as a quality assurance project (Reference: CT22_2018).

Consent for publication
Not applicable.

Competing interests
The authors have no conflict of interest to declare, apart from Dr Tahrani (AAT) who reports the following outside the submitted work. Grants from Novo Nordisk and Sanofi; personal fees from Novo Nordisk, Janssen, AZ, Eli Lilly, BI, BMS, NAPP, MSD. AAT is currently an employee of Novo Nordisk but this work was performed before he became a Novo Nordisk employee.

Author details
1School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia. 2South Western Sydney Metabolic Rehabilitation and Bariatric Program, Camden and Campbelltown Hospitals, Campbelltown, New South Wales, Australia. 3Australian Sleep Diagnostics, Campbelltown, New South Wales, Australia. 4Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK. 5Centre for Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners, Birmingham, UK. 6Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Trust, Birmingham, UK. 7Macarthur Clinical School, Western Sydney University, Parkside Crescent, 2560 Campbelltown, NSW, Australia.

Received: 22 September 2021 Accepted: 19 October 2021
Published online: 14 November 2021

References
1. Australian Institute of Health and Welfare: A picture of overweight and obesity in Australia. In: 2017. https://www.aihw.gov.au/getmedia/172fa28-785e-4ab8-ab37-2da3bbae408b/aihw-phe-216.pdf.aspx?inline=true. Accessed 17 Sept 2021.
2. Sampalis JS, Liberman M, Auger S, Christou NV. The impact of weight reduction surgery on health-care costs in morbidly obese patients. Obes Surg. 2004;14(7):939–47.
3. Nagayoshi M, Punjabi NM, Selvin E, Pankow JS, Shahar E, Iso H, Folsom AR, Lustey PL. Obstructive sleep apnea and incident type 2 diabetes. Sleep Med. 2016;25:156–61.
4. Phillips BG, Kato M, Nakreiwicz K, Choe I, Somers VK. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am J Physiol Heart Circ Physiol. 2000;279(1):H234–7.
5. Subramanian A, Adderley NJ, Tracy A, Taverner T, Hanif W, Toullis KA, Thomas GN, Tahraani AA, Narantharakumar K. Risk of incident obstructive sleep apnea among patients with type 2 diabetes. Diabetes Care. 2019;42(5):954–63.
6. Shajarawy H, Sarhan A, El Hawary A. Assessment of the effect of bariatric surgery on severe obstructive sleep apnea patients not tolerating CPAP therapy. Egypt J Chest Dis Tuberc. 2016;65(3):661–6.
7. Tregear S, Reston J, Schoelles K, Phillips B. Obstructive sleep apnea and risk of motor vehicle crash: systematic review and meta-analysis. J Clin Sleep Med. 2009;5(6):573–81.
8. Adderley NJ, Subramanian A, Toullis K, Gohale K, Taverner T, Hanif W, Haroon S, Thomas GN, Sainsbury C, Tahraani AA. Obstructive sleep apnea, a risk factor for cardiovascular and microvascular disease in patients with type 2 diabetes: findings from a population-based cohort study. Diabetes Care. 2020;43(8):1668–77.
9. Tahraani AA, Ali A, Raymond NT, Begum S, Dubb K, Mughal S, Jose B, Piya MK, Barnett AH, Stevens MJ. Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am J Respir Crit Care Med. 2012;186(5):A43–41.
10. Atfal QA, Dodson P, Ali A, Raymond NT, Wharton H, Fellows H, Hampshire-Bancroft R, Shah M, Shepherd E, Miah J. Obstructive sleep apnea and retinopathy in patients with type 2 diabetes. A longitudinal study. Am J Respir Crit Care Med. 2017;196(7):892–900.
11. Tahraani AA, Ali A, Raymond NT, Begum S, Dubb K, Atfal QA, Piya MK, Barnett AH, Stevens MJ. Obstructive sleep apnea and diabetic nephropathy: a cohort study. Diabetes Care. 2013;36(11):3718–25.
12. Netzer NC, Strohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999;131(7):485–91.
13. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–5.
14. Hamilton G, Joosten S. Obstructive sleep apnoea and obesity. Aust Fam Physician. 2017;46:460–3.
15. Sawyer AM, Gooneratne NS, Marcus CL, Ofer D, Richards KC, Weaver TE. A systematic review of CPAP adherence across age groups: clinical and empirical insights for developing CPAP adherence interventions. Sleep Med Rev. 2011;15(6):343–56.
16. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc. 2008;5(2):173–8.
17. Jennis P, Tannen H, Ilesen R, Kjellberg J. Obstructive sleep apnea: effect of comorbidities and positive airway pressure on all-cause mortality. Sleep Med. 2017;36:62–6.
18. Lavrentaki A, Ali A, Cooper BG, Tahraani AA. MECHANISMS OF ENDOCRINOLOGY: Mechanisms of disease: the endocrinology of obstructive sleep apnea. Eur J Endocrinol. 2019;180(3):R91–125.
19. Epstein LJ, Kristo D, Strollo PJ Jr., Friedman N, Malhotra A, Patil SP, Ramar K, Epstein LJ, Kristo D, Strollo PJ Jr., Friedman N, Malhotra A, Patil SP, Ramar K, Schub RB, Schwab RJ, Weaver EM, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263–76.
20. Peromaa-Haavisto P, Tuomilehto H, Kössi J, Virtanen J, Luostarinen M, Pihlajamäki J, Käkelä P, Victorzon M. Obstructive sleep apnea: the effect of bariatric surgery after 12 months. A prospective multicenter trial. Sleep. 2017;35:85–90.
21. Shneerson J, Wright JJ. Lifestyle modification for obstructive sleep apnoea. Cochrane Database Syst Rev 2001(1).
22. Mitchell LJ, Davidson ZE, Bonham M, O’Driscol DM, Hamilton GS, Truby H. Weight loss from lifestyle interventions and severity of sleep apnoea: a systematic review and meta-analysis. Sleep Med. 2014;15(10):1173–83.
23. Kajaste S, Brande PE, Telakivi T, Partinen M, Mustajoki P. A cognitive-behavioral weight reduction program in the treatment of obstructive sleep apnea syndrome with or without initial nasal CPAP: a randomized study. Sleep Med. 2004;5(2):125–31.
24. Zhu B, Shi C, Park CG, Zhao X, Neutrlak S. Effects of sleep restriction on metabolism-related parameters in healthy adults: A comprehensive review and meta-analysis of randomized controlled trials. Sleep Med Rev 2019.
25. Rihm JS, Miez MM, Schultz H, Bruder L, Schilbach L, Schmid SM, Peters J. Sleep Deprivation Selectively Upregulates an Amygdala-Hypothalamic Circuit Involved in Food Reward. J Neurosci. 2019;39(5):888–99.
26. Drager LF, Brunoni AR, Jenner R, Lorenzo-Filho G, Benseñor IM, Lotufo PA. Effects of CPAP on body weight in patients with obstructive sleep apnoea: a meta-analysis of randomised trials. Thorax. 2015;70(3):258–64.

27. Harsh IA, Konturek PC, Koebnick C, Kuennelein PP, Fuchs FS, Paur Schahn S, West GP, Hahn EG, Lohmann T, Ficker JH. Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur Respir J. 2003;22(2):251–7.

28. Henderson LA, Fatouleh RH, Lundblad LC, McKenzie DK, Macefield VG. Effects of 12 Months Continuous Positive Airway Pressure on Sympathetic Activity Related Brainstem Function and Structure in Obstructive Sleep Apnea. Front Neurosci. 2016;10(9).

29. Pyla MK, Chimonja R, Yu W, Grudzinskis K, Myint KP, Skelsey K, Kormas N, Hay P. Improvement in Eating Disorder Risk and Psychological Health in People with Class 3 Obesity: Effects of a Multidisciplinary Weight Management Program. Nutrients. 2021, 13(5).

30. Medveczky DM, Kodsi R, Skelsey K, Grudzinskis K, Bueno F, Ho V, Kormas N, Pyla MK. Class 3 Obesity in a Multidisciplinary Metabolic Weight Management Program: The Effect of Preeoeving Type 2 Diabetes on 6-Month Weight Loss. J Diabetes Res 2020, 2020.

31. Lih A, Pereira L, Bishay RH, Zang J, Omari A, Atlantis E, Kormas N. A novel multidisciplinary intervention for long-term weight loss and glycaemic control in obese patients with diabetes. J Diabetes Res 2015, 2015.

32. Beebe DW, Miller N, Kirk S, Daniels SR, Amin R. The association between obstructive sleep apnea and dietary choices among obese individuals during middle to late childhood. Sleep Med. 2011;12(8):797–9.

33. Beccuti G, Panaino S. Sleep and obesity. Curr Opin Clin Nutr Metab Care. 2011;14(4):402.

34. Phillips BG, Hisel TM, Kato M, Pesek CA, Dyken ME, Narkiewicz K, Somers VK. Recent weight gain in patients with newly diagnosed obstructive sleep apnea. J Hypertens. 1999;17(9):1297–300.

35. Stepnowsky CJ Jr, Moore PJ. Nasal CPAP treatment for obstructive sleep apnoea: developing a new perspective on dosing strategies and compliance. J Psychosom Res. 2003;54(6):599–605.

36. Tuomilehto H, Seppä J, Uusitupa M. Obesity and obstructive sleep apnea – clinical significance of weight loss. Sleep Med Rev. 2013;17(5):321–9.

37. Tahiani AA. Obstructive sleep apnoea in diabetes: does it matter? Diab Vasc Dis Res. 2017;14(5):454–62.

38. Padmi S, Tasali E. Obstructive sleep apnea and type 2 diabetes: is there a link? Front Neurol. 2012;3:126.

39. Anothaisintawee T, Reutrakul S, Van Cauter E, Thakkinstian A. Sleep disturbances compared to traditional risk factors for diabetes development: systematic review and meta-analysis. Sleep Med Rev. 2016;30:11–24.

40. Reutrakul S, Mokhlesi B. Obstructive sleep apnea and diabetes: a state of the art review. Chest. 2017;152(5):1070–86.

41. Morariu EM, Chasesi ER, Strollo PJ, Korytkowski M. Effect of continuous positive airway pressure (CPAP) on glycemic control and variability in type 2 diabetes. Sleep Breath. 2017;21(1):145–7.

42. Martinez-Cerón E, Barquiel B, Bézos A-M, Casitas R, Galera R, García-Benito C, Reutrakul S, Mokhlesi B. Obstructive sleep apnea and diabetes: a state of the art review. BMC Endocrine Disorders 2021, 21:227.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.